Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms

A 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Severity gradations for the MADRS have been proposed: 9-17 = mild depression, 18-34 = moderate depression, and ≥ 35 = severe depression. Scores range from 0-60 (higher scores are more symptomatic).

Response is defined as a 50% reduction or greater in MADRS score compared to baseline. Remission is defined as a MADRS score of <10.

Data are presented as a raw score point change.

19-item clinician administered assessment to measure the intensity, pervasiveness, and characteristics of suicidal ideation in adults.

Scores range from 0-38. Higher scores indicate more suicidality.

Data are presented as a raw score point change.

Clinical assessment measuring depressive symptoms. Scores range from 0-24 with scores >5 indicating clinical levels of depressive symptoms (higher scores are more symptomatic).

Data are presented as a raw score point change.

The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition.

There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items are given twice the weight of the others to compensate for poor cooperation from severely ill patients.

Typical YMRS baseline scores can vary a lot. They depend on the patients' clinical features such as mania (YMRS = 12), depression (YMRS = 3), or euthymia (YMRS = 2).

Data are presented as a raw score point change.

The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.

Scores: 0-13= minimal depression, 14-19=mild depression, 20-28=moderate depression, 29-63=severe depression.

Data are presented as a raw score point change.

Self-report measure of depressive symptoms. The questionnaire consists of 16 questions. Each question can score between 0 to 4 points.

Severity of depression is determined as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Very Severe.

Total scores range from 0-27. Total scores: 0-5= no depression, 6-10= mild depression, 11-15= moderate depression, 16-20= severe depression, 21-27= very severe depression.

The total score is obtained by adding the scores for each of the nine symptom domains of the DSM-IV MDD criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes (Rush et al. 2003).

Data are presented as a raw score point change.

Self-report, 20 item scale to determine patient's insomnia level.

Each question can be scored between 0-3. 0=not bothered at all

slightly bothered moderately bothered severely bothered

Total score is calculated by adding up all questions (i.e. Q1+Q2+...Q20). One missing item is allowed, pro-rate if missing one item....i.e. (sum/count)*20.

Minimum Score = 0 (good); Maximum Score = 60 (bad).

Data are presented as a raw score point change.

For the first and last stimulation session, EEG recording will be made before (resting-state EEG) and during (TMS-evoked potentials) the stimulation.

Blood (plasma) samples will be collected before and one month after stimulation. Blood collection is conducted by the registered hospital phlebotomist (following same protocol of a routine blood test).

Blood samples will be analyzed by our collaborators at the Open Medicine Institute. Specifically, samples will be used for DNA/RNA extraction and analyses will be done to determine potential gene targets. Presence of inflammatory markers (cytokines) will also be determined.

All analyses of blood samples will be conducted in the Open Medicine Institute.

Stool samples will be collected before and one month after stimulation. Stool collection is performed by registered hospital nurses.

Stool samples will be analyzed by our collaborators at the Open Medicine Institute. Specifically, stool samples will be analyzed for potential biomarkers in the gut microbiome.

All analyses of stool samples will be conducted in the Open Medicine Institute.

Saliva samples will be collected before and one month after stimulation. Saliva collection is performed by registered study personnel.

Saliva samples will be analyzed by our collaborators at the Open Medicine Institute. Specifically, saliva samples will be analyzed for cortisol levels.

All analyses of stool samples will be conducted in the Open Medicine Institute.

15-item self-report questionnaire where each item is scored from very poor=1 to very good=5.

The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score.

The last two items are not included in the total score but are stand-alone items.

The raw total score ranges from 14 (min) to 70 (max).

Neurocognitive assessments delivered through an iPad app

Immediate Mood Scaler (IMS) is a newly developed, iPad-deliverable 12-item self-report tool designed to capture current mood states with overall score, and depression and anxiety subscales. Individual item scores range from 1-7, with a total overall score range from 12-84.

Data are presented as a raw score point change in depression subscale score. The depression subscale scores range from 7-49 (higher score indicating worse depression).

Measure presence of any change in heart rate variability.

Data is reported as a ratio of low frequency (LF) and high frequency (HF) (LF/HF FFT).

FFT: fast Fourier transform.

If participants have a co-morbid diagnosis of drug abuse this self-report questionnaire will be used to monitor craving of their particular drug of abuse.

If participants have a co-morbid diagnosis of borderline personality disorder this self-report questionnaire will be used to monitor symptoms.

If participants have a co-morbid diagnosis of drug abuse this self-report questionnaire will be used.

If participants have a co-morbid diagnosis of drug abuse their reported average weekly substance use will be recorded.

If participants have a co-morbid diagnosis of an eating disorder, this self-report questionnaire will be used to monitor symptoms.

If participants have a co-morbid diagnosis of Anxiety, this self-report scale will be used to monitor anxiety symptoms.

If participants have a co-morbid diagnosis of an eating disorder, this clinician-rated assessment will be used to monitor symptoms.

If participants have a co-morbid diagnosis of an impulse disorder, this self-report questionnaire will be used to monitor symptoms.

If participants have a co-morbid diagnosis of OCD, this self-report questionnaire will be used to monitor symptoms.

If participants have a co-morbid diagnosis of OCD, this clinician-rated scale will be used to monitor symptoms.

If participants have a co-morbid diagnosis of a pain disorder, this rating scale will be used to monitor symptoms.

If participants have a co-morbid diagnosis of a panic disorder, this rating scale will be used to monitor symptoms.

If participants have a co-morbid diagnosis of PTSD, this self-report questionnaire will be used to monitor symptoms.

If participants have a co-morbid diagnosis of Schizophrenia, this assessment will be used to monitor symptoms.

If participants have a co-morbid diagnosis of Schizophrenia, this clinician-rated assessment will be used to monitor symptoms.